DOCSLIB.ORG

ZBTB7A Mediates the Transcriptional Repression Activity of the Androgen Receptor in Prostate

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
ZBTB7A Mediates the Transcriptional Repression Activity of the Androgen Receptor in Prostate Author Manuscript Published OnlineFirst on August 23, 2019; DOI: 10.1158/0008-5472.CAN-19-0815 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. ZBTB7A Mediates the Transcriptional Repression Activity of the Androgen Receptor in Prostate Cancer Dong Han1, Sujun Chen2,3, Wanting Han1, Shuai Gao1, Jude N. Owiredu1, Muqing Li1, Steven P. Balk4, Housheng Hansen He2,3, and Changmeng Cai1 1 Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, Massachusetts 02125, USA; 2 Princess Margaret Cancer Center/University Health Network, Toronto, Ontario M5G1L7, Canada; 3 Department of Medical Biophysics, University of Toronto, Toronto, Ontario M5S, Canada; 4 Beth Israel Deaconess Medical Center, Boston, MA 02215 D.H., S.C., and W.H. contributed equally to this work. Correspondence: Changmeng Cai, Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, Massachusetts 02125, USA, ([email protected]); Housheng Hansen He, Princess Margaret Cancer Center/University Health Network, Toronto, Ontario M5G1L7, Canada, ([email protected]) Running Title: ZBTB7A Mediates AR Transcriptional Repression Activity Key Words: ZBTB7A, Rb, E2F1, prostate cancer, androgen receptor, AR, androgen-deprivation therapy, high dose testosterone, DNA replication 1 Downloaded from cancerres.aacrjournals.org on September 29, 2021. © 2019 American Association for Cancer Research. Author Manuscript Published OnlineFirst on August 23, 2019; DOI: 10.1158/0008-5472.CAN-19-0815 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. ABSTRACT Loss of expression of context-specific tumor suppressors is a critical event that facilitates the development of prostate cancer (PCa). Zinc finger and BTB domain containing transcriptional repressors, such as ZBTB7A and ZBTB16, have been recently identified as tumor suppressors that play important roles in preventing PCa progression. In this study, we used combined ChIP-seq and RNA-seq analyses of PCa cells to identify direct ZBTB7A-repressed genes which are enriched for transcriptional targets of E2F and identified that the androgen receptor (AR) played a critical role in the transcriptional suppression of these E2F targets. AR recruitment of the Retinoblastoma protein (Rb) was required to strengthen the E2F-Rb transcriptional repression complex. In addition, ZBTB7A was rapidly recruited to the E2F-Rb binding sites by AR and negatively regulated the transcriptional activity of E2F1 on DNA replication genes. Finally, ZBTB7A suppressed the growth of castration-resistant PCa (CRPC) in vitro and in vivo, and overexpression of ZBTB7A acted in synergy with high-dose testosterone treatment to effectively prevent the recurrence of CRPC. Overall, this study provides novel molecular insights of the role of ZBTB7A in CRPC cells and demonstrates globally its critical role in mediating the transcriptional repression activity of AR. SIGNIFICANCE ZBTB7A is recruited to the E2F-Rb binding sites by AR and negatively regulates the transcriptional activity of E2F1 on DNA replication genes. INTRODUCTION Prostate cancer (PCa) is one of the most common cancers in men. The development of primary PCa depends on the activity of androgen receptor (AR), a ligand-dependent nuclear receptor transcription factor. The standard treatment of PCa is surgical or medical castration (known as androgen deprivation therapy, ADT) to reduce circulating androgens. However, patients invariably relapse into more aggressive castration-resistant prostate cancer (CRPC) with increased expression and restored activity of AR (1). Although CRPC can be further treated with more aggressive ADT using agents such as abiraterone and enzalutamide (2,3), the tumors still generally relapse within one year and a large portion of these relapsed tumors still express AR and AR 2 Downloaded from cancerres.aacrjournals.org on September 29, 2021. © 2019 American Association for Cancer Research. Author Manuscript Published OnlineFirst on August 23, 2019; DOI: 10.1158/0008-5472.CAN-19-0815 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. regulated genes. While AR is known for its transcriptional activator function, it can also act as a transcriptional repressor to suppress the expression of a subset of genes, including AR itself, androgen synthetic genes, and genes mediating DNA replication and repair (4,5). Mechanistically, we have shown that AR globally recruits hypophosphorylated Retinoblastoma protein (Rb) to the promoters/enhancers of DNA replication gene loci and strengthens the activity of E2F-Rb suppressor complex (6). Therefore, loss of this tumor suppressor activity of AR after ADT is likely to be one mechanism contributing to the progression to CRPC (1). This transcriptional repressor activity of AR also provides one of the mechanisms for the high-dose testosterone therapy in CRPC patients (7-10). In addition to AR, the recently reported zinc finger and BTB domain containing transcription repressors, such as ZBTB7A and ZBTB16, can also function as tumor suppressors in preventing the progression of PCa (11-14). ZBTB7A, also known as LRF/POKEMON, consists of a protein-protein interacting BTB domain at the N-terminus and DNA binding zinc fingers at the C-terminus (13). Even though ZBTB7A has been identified as a proto-oncogene in other cancer types, a recent study using a transgenic mouse model indicates that it functions as a tumor suppressor in PCa and that loss of its expression can drive the development of aggressive invasive tumor in Pten-null prostate epithelial cells by bypassing the Pten-loss induced cellular senescence (15). Mechanistically, ZBTB7A was shown to repress the activity of SOX9, a proto-oncogene in PCa (16), and to impair the SOX9 regulation of an RB-targeting miRNA, thus allowing cells to bypass the Pten- loss induced senescence (15). Although its tumor suppressor activity has been demonstrated in mouse PCa cells, the activities of ZBTB7A at the chromatin level in human PCa cells remain to be characterized. Using a combined analysis of the ZBTB7A cistrome and transcriptome, we have mapped the binding sites of ZBTB7A and identified direct ZBTB7A-regulated genes. Significantly, the direct ZBTB7A-repressed genes were enriched for the activation function of E2Fs, suggesting that ZBTB7A may function to repress their oncogenic activities in PCa cells. Since our previous studies indicated AR can function as a transcriptional repressor to suppress DNA replication genes through enhancing the chromatin binding of Rb that reinforces the suppressor activity of E2F- Rb complex (6), we next determined how ZBTB7A chromatin binding in PCa cells globally impacts the transcriptional activity of AR. By co-analyzing the previous reported AR cistrome database in PCa cells (4,16), 3 Downloaded from cancerres.aacrjournals.org on September 29, 2021. © 2019 American Association for Cancer Research. Author Manuscript Published OnlineFirst on August 23, 2019; DOI: 10.1158/0008-5472.CAN-19-0815 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. we show that a significant portion of ZBTB7A binding sites overlap with AR binding sites and that these ZBTB7A and AR overlapping sites are significantly associated with the repression activity of AR on gene transcription. More importantly, we also show that ZBTB7A binding at those AR repression sites is rapidly increased upon androgen stimulation and the increased binding is highly associated with E2F-Rb binding, indicating that AR-recruited ZBTB7A may cooperate with Rb in regulating the transcriptional activity of E2Fs. By co-immunoprecipitation assays, we demonstrated that ZBTB7A can physically interact with AR, Rb, and E2F1, further indicating that ZBTB7A may be an additional component of the AR-Rb repressor complex. Furthermore, we carried out in vitro and in vivo studies to examine the effects of overexpression of ZBTB7A on CRPC tumor growth and results show that overexpression of ZBTB7A in CRPC cells significantly reduced the cancer development, and that overexpression of ZBTB7A can synergize with high-dose testosterone therapy in treating CRPC. Overall, this study has provided novel insights into the tumor suppressor activity of ZBTB7A in PCa cells and identified ZBTB7A as a critical mediator required for AR-dependent transcriptional repression activity. MATERIALS AND METHODS Cell lines and cell culture: The VCaP and C4-2 cell lines were purchased from ATCC. All the cell lines were recently authenticated using short tandem repeat (STR) profiling by DDC Medical and tested for mycoplasma contamination (negative result) by using MycoAlert mycoplasma detection kit (Lonza). VCaP cells were cultured in DMEM medium with 10% FBS (fetal bovine serum, Gibco). VCaP-tet-shZBTB7A (tetracycline- inducible ZBTB7A silencing) cells were maintained in DMEM medium with 10% tetracycline-free FBS. C4-2 and C4-2-shZBTB7A (stable ZBTB7A silencing) cells were cultured in RPMI-1640 medium supplemented with 2% FBS plus 8% CSS (charcoal-dextran stripped FBS, Gibco). C4-2-tet-ZBTB7A (tetracycline-inducible ZBTB7A overexpressing) cells were maintained in RPMI-1640 medium with 2% tetracycline-free FBS plus 8% CSS. For androgen stimulation assays, cells were generally grown to 50-60% confluence in medium containing 5% CSS for 2-3 days (d) and then treated with DHT or inhibitors for indicated time. 4 Downloaded from
Load more

Recommended publications
  • Impact of ZBTB7A Hypomethylation and Expression Patterns on Treatment Response to Hydroxyurea Vasiliki Chondrou1†, Eleana F
    Chondrou et al. Human Genomics (2018) 12:45 https://doi.org/10.1186/s40246-018-0177-z PRIMARY RESEARCH Open Access Impact of ZBTB7A hypomethylation and expression patterns on treatment response to hydroxyurea Vasiliki Chondrou1†, Eleana F. Stavrou1†, Georgios Markopoulos2, Alexandra Kouraklis-Symeonidis3, Vasilios Fotopoulos4, Argiris Symeonidis5, Efthymia Vlachaki6, Panagiota Chalkia7, George P. Patrinos8, Adamantia Papachatzopoulou9 and Argyro Sgourou1* Abstract Background: We aimed to clarify the emerging epigenetic landscape in a group of genes classified as “modifier genes” of the β-type globin genes (HBB cluster), known to operate in trans to accomplish the two natural developmental switches in globin expression, from embryonic to fetal during the first trimester of conception and from fetal to adult around the time of birth. The epigenetic alterations were determined in adult sickle cell anemia (SCA) homozygotes and SCA/β-thalassemia compound heterozygotes of Greek origin, who are under hydroxyurea (HU) treatment. Patients were distinguished in HU responders and HU non-responders (those not benefited from the HU) and both, and in vivo and in vitro approaches were implemented. Results: We examined the CpG islands’ DNA methylation profile of BCL11A, KLF1, MYB, MAP3K5, SIN3A, ZBTB7A,andGATA2, along with γ-globin and LRF/ZBTB7A expression levels. In vitro treatment of hematopoietic stem cells (HSCs) with HU induced a significant DNA hypomethylation pattern in ZBTB7A (p*, 0.04) and GATA2 (p*, 0.03) CpGs exclusively in the HU non-responders. Also, this group of patients exhibited significantly elevated baseline methylation patterns in ZBTB7A, before the HU treatment, compared to HU responders (p*, 0.019) and to control group of healthy individuals (p*, 0.021) , which resembles a potential epigenetic barrier for the γ-globin expression.
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • The BTB-ZF Family of Transcription Factors: Key Regulators of Lineage
    The BTB-ZF Family of Transcription Factors: Key Regulators of Lineage Commitment and Effector Function Development in the Immune System This information is current as of September 27, 2021. Aimee M. Beaulieu and Derek B. Sant'Angelo J Immunol 2011; 187:2841-2847; ; doi: 10.4049/jimmunol.1004006 http://www.jimmunol.org/content/187/6/2841 Downloaded from References This article cites 103 articles, 44 of which you can access for free at: http://www.jimmunol.org/content/187/6/2841.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 27, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2011 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The BTB-ZF Family of Transcription Factors: Key Regulators of Lineage Commitment and Effector Function Development in the Immune System Aimee M. Beaulieu* and Derek B. Sant’Angelo*,†,‡ Successful immunity depends upon the activity of mul- 1, -2, -4, -5, and -7 (1–11).
    [Show full text]
  • SUPPLEMENTARY NOTE Co-Activation of GR and NFKB
    SUPPLEMENTARY NOTE Co-activation of GR and NFKB alters the repertoire of their binding sites and target genes. Nagesha A.S. Rao1*, Melysia T. McCalman1,*, Panagiotis Moulos2,4, Kees-Jan Francoijs1, 2 2 3 3,5 Aristotelis Chatziioannou , Fragiskos N. Kolisis , Michael N. Alexis , Dimitra J. Mitsiou and 1,5 Hendrik G. Stunnenberg 1Department of Molecular Biology, Radboud University Nijmegen, the Netherlands 2Metabolic Engineering and Bioinformatics Group, Institute of Biological Research and Biotechnology, National Hellenic Research Foundation, Athens, Greece 3Molecular Endocrinology Programme, Institute of Biological Research and Biotechnology, National Hellenic Research Foundation, Greece 4These authors contributed equally to this work 5 Corresponding authors E-MAIL: [email protected] ; TEL: +31-24-3610524; FAX: +31-24-3610520 E-MAIL: [email protected] ; TEL: +30-210-7273741; FAX: +30-210-7273677 Running title: Global GR and NFKB crosstalk Keywords: GR, p65, genome-wide, binding sites, crosstalk SUPPLEMENTARY FIGURES/FIGURE LEGENDS AND SUPPLEMENTARY TABLES 1 Rao118042_Supplementary Fig. 1 A Primary transcript Mature mRNA TNF/DMSO TNF/DMSO 8 12 r=0.74, p< 0.001 r=0.61, p< 0.001 ) 2 ) 10 2 6 8 4 6 4 2 2 0 Fold change (mRNA) (log Fold change (primRNA) (log 0 −2 −2 −2 0 2 4 −2 0 2 4 Fold change (RNAPII) (log2) Fold change (RNAPII) (log2) B chr5: chrX: 56 _ 104 _ DMSO DMSO 1 _ 1 _ 56 _ 104 _ TA TA 1 _ 1 _ 56 _ 104 _ TNF TNF Cluster 1 1 _ Cluster 2 1 _ 56 _ 104 _ TA+TNF TA+TNF 1 _ 1 _ CCNB1 TSC22D3 chr20: chr17: 25 _ 33 _ DMSO DMSO 1 _ 1 _ 25 _ 33 _ TA TA 1 _ 1 _ 25 _ 33 _ TNF TNF Cluster 3 1 _ Cluster 4 1 _ 25 _ 33 _ TA+TNF TA+TNF 1 _ 1 _ GPCPD1 CCL2 chr6: chr22: 77 _ 35 _ DMSO DMSO 1 _ 77 _ 1 _ 35 _ TA TA 1 _ 1 _ 77 _ 35 _ TNF Cluster 5 Cluster 6 TNF 1 _ 1 _ 77 _ 35 _ TA+TNF TA+TNF 1 _ 1 _ TNFAIP3 DGCR6 2 Supplementary Figure 1.
    [Show full text]
  • Structural Basis of Specific DNA Binding by the Transcription Factor
    8388–8398 Nucleic Acids Research, 2019, Vol. 47, No. 16 Published online 21 June 2019 doi: 10.1093/nar/gkz557 Structural basis of specific DNA binding by the transcription factor ZBTB24 Ren Ren1,†, Swanand Hardikar1,†, John R. Horton1, Yue Lu1, Yang Zeng1,2,AnupK.Singh1, Kevin Lin1, Luis Della Coletta1, Jianjun Shen1,2, Celine Shuet Lin Kong3, Hideharu Hashimoto4, Xing Zhang1, Taiping Chen1,2,* and Xiaodong Cheng 1,2,* 1Department of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, 2 Houston, TX 77030, USA, Program in Genetics and Epigenetics, The University of Texas MD Anderson Cancer Downloaded from https://academic.oup.com/nar/article/47/16/8388/5521786 by guest on 23 September 2021 Center UTHealth Graduate School of Biomedical Sciences, Houston, TX 77030, USA, 3Program in Cancer Biology, The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, TX 77030, USA and 4Department of Biochemistry, Emory University School of Medicine, Atlanta, GA 30322, USA Received October 13, 2018; Revised June 07, 2019; Editorial Decision June 11, 2019; Accepted June 13, 2019 ABSTRACT INTRODUCTION ZBTB24, encoding a protein of the ZBTB family ZBTB (zinc-finger- and BTB domain-containing) proteins, of transcriptional regulators, is one of four known characterized by the presence of an N-terminal BTB genes––the other three being DNMT3B, CDCA7 and (broad-complex, tram-track, and bric-a-brac)` domain [also HELLS––that are mutated in immunodeficiency, cen- known as POZ (poxvirus and zinc finger) domain] and a tromeric instability and facial anomalies (ICF) syn- C-terminal domain with tandem C2H2 Kr¨uppel-type zinc fingers (ZFs), are a large family of evolutionarily con- drome, a genetic disorder characterized by DNA hy- served transcriptional regulators (1).
    [Show full text]
  • Virtual Chip-Seq: Predicting Transcription Factor Binding
    bioRxiv preprint doi: https://doi.org/10.1101/168419; this version posted March 12, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 1 Virtual ChIP-seq: predicting transcription factor binding 2 by learning from the transcriptome 1,2,3 1,2,3,4,5 3 Mehran Karimzadeh and Michael M. Hoffman 1 4 Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada 2 5 Princess Margaret Cancer Centre, Toronto, ON, Canada 3 6 Vector Institute, Toronto, ON, Canada 4 7 Department of Computer Science, University of Toronto, Toronto, ON, Canada 5 8 Lead contact: michael.hoff[email protected] 9 March 8, 2019 10 Abstract 11 Motivation: 12 Identifying transcription factor binding sites is the first step in pinpointing non-coding mutations 13 that disrupt the regulatory function of transcription factors and promote disease. ChIP-seq is 14 the most common method for identifying binding sites, but performing it on patient samples is 15 hampered by the amount of available biological material and the cost of the experiment. Existing 16 methods for computational prediction of regulatory elements primarily predict binding in genomic 17 regions with sequence similarity to known transcription factor sequence preferences. This has limited 18 efficacy since most binding sites do not resemble known transcription factor sequence motifs, and 19 many transcription factors are not even sequence-specific. 20 Results: 21 We developed Virtual ChIP-seq, which predicts binding of individual transcription factors in new 22 cell types using an artificial neural network that integrates ChIP-seq results from other cell types 23 and chromatin accessibility data in the new cell type.
    [Show full text]
  • The Tumor Suppressor HHEX Inhibits Axon Growth When Prematurely Expressed in Developing Central Nervous System Neurons
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by epublications@Marquette Marquette University e-Publications@Marquette Biological Sciences Faculty Research and Biological Sciences, Department of Publications 9-1-2015 The umorT Suppressor HHEX Inhibits Axon Growth when Prematurely Expressed in Developing Central Nervous System Neurons Matthew .T Simpson Marquette University Ishwariya Venkatesh Marquette University Ben L. Callif Marquette University Laura K. Thiel Marquette University Denise M. Coley Marquette University See next page for additional authors Accepted version. Molecular and Cellular Neuroscience, Vol 68 )September 2015): 272-283. DOI. © 2015 Elsevier Inc. Used with permission. NOTICE: this is the author’s version of a work that was accepted for publication in Molecular and Cellular Neuroscience. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in Molecular and Cellular Neuroscience, Vol 68 )September 2015): 272-283. DOI. Authors Matthew T. Simpson, Ishwariya Venkatesh, Ben L. Callif, Laura K. Thiel, Denise M. Coley, Kristen N. Winsor, Zimei Wang, Audra A. Kramer, Jessica K. Lerch, and Murray G. Blackmore This article is available at e-Publications@Marquette: https://epublications.marquette.edu/bio_fac/515 NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be accessed by following the link in the citation at the bottom of the page. The Tumor Suppressor HHEX Inhibits Axon Growth When Prematurely Expressed in Developing Central Nervous System Neurons Matthew T.
    [Show full text]
  • In Vitro Targeting of Transcription Factors to Control the Cytokine Release Syndrome in 2 COVID-19 3
    bioRxiv preprint doi: https://doi.org/10.1101/2020.12.29.424728; this version posted December 30, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC 4.0 International license. 1 In vitro Targeting of Transcription Factors to Control the Cytokine Release Syndrome in 2 COVID-19 3 4 Clarissa S. Santoso1, Zhaorong Li2, Jaice T. Rottenberg1, Xing Liu1, Vivian X. Shen1, Juan I. 5 Fuxman Bass1,2 6 7 1Department of Biology, Boston University, Boston, MA 02215, USA; 2Bioinformatics Program, 8 Boston University, Boston, MA 02215, USA 9 10 Corresponding author: 11 Juan I. Fuxman Bass 12 Boston University 13 5 Cummington Mall 14 Boston, MA 02215 15 Email: [email protected] 16 Phone: 617-353-2448 17 18 Classification: Biological Sciences 19 20 Keywords: COVID-19, cytokine release syndrome, cytokine storm, drug repurposing, 21 transcriptional regulators 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.12.29.424728; this version posted December 30, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC 4.0 International license. 22 Abstract 23 Treatment of the cytokine release syndrome (CRS) has become an important part of rescuing 24 hospitalized COVID-19 patients. Here, we systematically explored the transcriptional regulators 25 of inflammatory cytokines involved in the COVID-19 CRS to identify candidate transcription 26 factors (TFs) for therapeutic targeting using approved drugs.
    [Show full text]
  • Keep Your Fingers Off My DNA: Protein-Protein Interactions
    1 2 Keep your fingers off my DNA: 3 protein-protein interactions mediated by C2H2 zinc finger domains 4 5 6 a scholarly review 7 8 9 10 11 Kathryn J. Brayer1 and David J. Segal2* 12 13 14 15 16 17 1Department of Pharmacology and Toxicology, College of Pharmacy, University of Arizona, 18 Tucson, AZ, 85721. 19 2Genome Center and Department of Pharmacology, University of California, Davis, CA, 95616. 20 21 22 23 24 *To whom correspondence should be addressed: 25 David J. Segal, Ph.D. 26 University of California, Davis 27 Genome Center/Pharmacology 28 4513 GBSF 29 451 E. Health Sciences Dr. 30 Davis, CA 95616 31 Tel: 530-754-9134 32 Fax: 530-754-9658 33 Email: [email protected] 34 35 36 Running header: C2H2 ZF interactions with proteins 37 38 Keywords: transcription factors, protein-DNA interactions, protein chemistry, structural biology, 39 functional annotations 40 41 Abstract: 154 words 42 Body Text: 5863 words 43 Figures: 9 44 Tables: 5 45 References: 165 46 C2H2 ZF interactions with proteins Brayer and Segal - review 46 ABSTRACT 47 Cys2-His2 (C2H2) zinc finger domains were originally identified as DNA binding 48 domains, and uncharacterized domains are typically assumed to function in DNA binding. 49 However, a growing body of evidence suggests an important and widespread role for these 50 domains in protein binding. There are even examples of zinc fingers that support both DNA and 51 protein interactions, which can be found in well-known DNA-binding proteins such as Sp1, 52 Zif268, and YY1. C2H2 protein-protein interactions are proving to be more abundant than 53 previously appreciated, more plastic than their DNA-binding counterparts, and more variable and 54 complex in their interactions surfaces.
    [Show full text]
  • Hp1γ Promotes Lung Adenocarcinoma by Downregulating the Transcription-Repressive
    Author Manuscript Published OnlineFirst on May 15, 2018; DOI: 10.1158/0008-5472.CAN-17-3571 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. HP1γ promotes lung adenocarcinoma by downregulating the transcription-repressive regulators NCOR2 and ZBTB7A Hunain Alam1, Na Li1, Shilpa S. Dhar1, Sarah J. Wu1,2, Jie Lv3,4,5, Kaifu Chen3,4,5, Elsa R. Flores6, Laura Baseler7,8, and Min Gyu Lee1,2 1Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, TX, USA. 2The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, TX, USA. 3Institute for Academic Medicine, The Methodist Hospital Research Institute, Houston, TX, USA. 4Center for Cardiovascular Regeneration, Department of Cardiovascular Sciences, The Methodist Hospital Research Institute, Houston, TX, USA. 5Weill Cornell Medical College, Cornell University, New York, NY, USA. 6Department of Molecular Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA. 7Department of Veterinary Medicine and Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 8Current address: University of British Columbia, School of Population and Public Health, 2329 West Mall Vancouver, British Columbia V6T 1Z4, Canada; Animal Health Centre, Ministry of Agriculture, 1767 Angus Campbell Rd., Abbotsford, British Columbia V3G 2M3, Canada. Running title: Pro-tumorigenic function of HP1γ for lung adenocarcinoma Corresponding Author: Min Gyu Lee, Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030. Phone: 713-792-3678 Fax: 713-794-3270 Email: [email protected] The authors declare no potential conflicts of interest.
    [Show full text]
  • ZBTB7A Acts As a Tumor Suppressor Through the Transcriptional Repression of Glycolysis
    Downloaded from genesdev.cshlp.org on October 4, 2021 - Published by Cold Spring Harbor Laboratory Press ZBTB7A acts as a tumor suppressor through the transcriptional repression of glycolysis Xue-Song Liu,1 Jenna E. Haines,1 Elie K. Mehanna,1 Matthew D. Genet,1 Issam Ben-Sahra,1 John M. Asara,2 Brendan D. Manning,1 and Zhi-Min Yuan1 1Department of Genetics and Complex Diseases, Harvard School of Public Health, Boston, Massachusetts 02115, USA; 2Division of Signal Transduction, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02115, USA Elevated glycolysis is a common metabolic trait of cancer, but what drives such metabolic reprogramming remains incompletely clear. We report here a novel transcriptional repressor-mediated negative regulation of glycolysis. ZBTB7A, a member of the POK (POZ/BTB and Kruppel)€ transcription repressor family, directly binds to the promoter and represses the transcription of critical glycolytic genes, including GLUT3, PFKP, and PKM. Analysis of The Cancer Genome Atlas (TCGA) data sets reveals that the ZBTB7A locus is frequently deleted in many human tumors. Significantly, reduced ZBTB7A expression correlates with up-regulation of the glycolytic genes and poor survival in colon cancer patients. Remarkably, while ZBTB7A-deficient tumors progress exceedingly fast, they exhibit an unusually heightened sensitivity to glycolysis inhibition. Our study uncovers a novel tumor suppressor role of ZBTB7A in directly suppressing glycolysis. [Keywords: glycolysis; tumor suppressor; ZBTB7A; GLUT3; PFKP; PKM] Supplemental material is available for this article. Received May 21, 2014; revised version accepted August 8, 2014. Metabolic reprograming is a hallmark of human cancer phosphorylation by inducing the expression of synthesis and accelerated aerobic glycolysis (or the Warburg effect) of cytochrome c oxidase (SCO2) and the TP53-induced and is frequently observed in multiple types of cancer glycolysis and apoptosis regulator (TIGAR) that inhibits (Hanahan and Weinberg 2011).
    [Show full text]
  • Identification of Genomic Targets of Krüppel-Like Factor 9 in Mouse Hippocampal
    Identification of Genomic Targets of Krüppel-like Factor 9 in Mouse Hippocampal Neurons: Evidence for a role in modulating peripheral circadian clocks by Joseph R. Knoedler A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy (Neuroscience) in the University of Michigan 2016 Doctoral Committee: Professor Robert J. Denver, Chair Professor Daniel Goldman Professor Diane Robins Professor Audrey Seasholtz Associate Professor Bing Ye ©Joseph R. Knoedler All Rights Reserved 2016 To my parents, who never once questioned my decision to become the other kind of doctor, And to Lucy, who has pushed me to be a better person from day one. ii Acknowledgements I have a huge number of people to thank for having made it to this point, so in no particular order: -I would like to thank my adviser, Dr. Robert J. Denver, for his guidance, encouragement, and patience over the last seven years; his mentorship has been indispensable for my growth as a scientist -I would also like to thank my committee members, Drs. Audrey Seasholtz, Dan Goldman, Diane Robins and Bing Ye, for their constructive feedback and their willingness to meet in a frequently cold, windowless room across campus from where they work -I am hugely indebted to Pia Bagamasbad and Yasuhiro Kyono for teaching me almost everything I know about molecular biology and bioinformatics, and to Arasakumar Subramani for his tireless work during the home stretch to my dissertation -I am grateful for the Neuroscience Program leadership and staff, in particular
    [Show full text]